|
|
|
Stem Cell Related Patent Number US7101704
| Title: | Antigen presenting mesenchymal stem cells | | Inventors: | Mosca, Joseph; Ellicott City, MD, USA | | Summary: | Described herein is a novel composition comprising an antigen-presenting mesenchymal stem cell of the adipocyte lineage and which expresses at least one co-stimulatory molecule. The mesenchymal stem cell described herein has been modified to have at least one exogenous antigen bound to at least one primary surface molecule such that at least one antigen can initiate an immune response while also expressing at least one co-stimulatory molecule. The antigen is described as preferably being a protein, a polypeptide, a lipid or a glycolipid, with a primary surface molecule of MHC I, MHC II or CD1. Further described is a method by which the mesenchymal stem cell may be contacted with interferon-gamma, and methods by which the state of activation of a T lymphocyte population may be determined. Applications for the treatment and prevention of various diseases are described, utilizing the immune response elicited by the antigen described herein. | | Abstract: | Disclosed is a mesenchymal stem cell and/or cell of the adipocyte lineage that (i) has been modified to have at least one exogenous antigen bound to at least one primary surface molecule of said cell such that said at least one antigen can initiate an immune response and (ii) also expresses at least one co-stimulatory molecule. The antigen is preferably a protein, polypeptide, lipid or glycolipid. The primary surface molecule is MHC I, MHC II or CD1. Also disclosed is a method for stimulating presentation of at least one exogenous antigen fragment on a mesenchymal stem cell primary surface molecule by contacting a mesenchymal stem cell that is capable of expressing at least one co-stimulatory molecule with (i) an exogenous antigen or (ii) genetic material that codes for the exogenous antigen which the mesenchymal stem cell processes into at least one antigen fragment. The method can further include contacting the mesenchymal stem cell with interferon-γ. Also disclosed are a method for determining the state of activation of a T lymphocyte population and a method for the treatment or prevention of a disease in an animal. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US7101704 | | Application Number: | US2000000638358 | | Date Filed: | 15/08/2000 | | Date Published: | 05/09/2006 | | Assignee: | Osiris Therapeutics, Inc., Baltimore, MD, USA |
|
|
